BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bermejo JL, Sundquist J, Hemminki K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer 2009;101:1091-9. [PMID: 19755987 DOI: 10.1038/sj.bjc.6605325] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen T, Kharazmi E, Lou J, Zhang X, Sundquist K, Hemminki K. Risk of second primary cancers after malignant mesothelioma and vice versa. Cancer Letters 2016;379:94-9. [DOI: 10.1016/j.canlet.2016.05.034] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
2 Queiroz RM, Roque D, Febronio EM. Multiple primary malignancies: synchronous urothelial carcinoma of the bladder and adenocarcinoma of the colon. Radiol Bras 2017;50:64. [PMID: 28298737 DOI: 10.1590/0100-3984.2015.0114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Zelefsky MJ, Housman DM, Pei X, Alicikus Z, Magsanoc JM, Dauer LT, St. Germain J, Yamada Y, Kollmeier M, Cox B, Zhang Z. Incidence of Secondary Cancer Development After High-Dose Intensity-Modulated Radiotherapy and Image-Guided Brachytherapy for the Treatment of Localized Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 2012;83:953-9. [DOI: 10.1016/j.ijrobp.2011.08.034] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
4 Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, Radford J, van Leeuwen FE. Current knowledge and future research directions in treatment-related second primary malignancies. EJC Suppl 2014;12:5-17. [PMID: 26217162 DOI: 10.1016/j.ejcsup.2014.05.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
5 Chen T, Fallah M, Sundquist K, Liu H, Hemminki K. Risk of subsequent cancers in renal cell carcinoma survivors with a family history. Eur J Cancer 2014;50:2108-18. [PMID: 24923229 DOI: 10.1016/j.ejca.2014.05.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
6 Harlos CH, Singh H, Nugent Z, Demers A, Mahmud SM, Czaykowski PM. The risk of colorectal cancer is not increased after a diagnosis of urothelial cancer: a population-based study. Curr Oncol 2016;23:391-7. [PMID: 28050135 DOI: 10.3747/co.23.3304] [Reference Citation Analysis]
7 Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, Morgans AK, Penson DF. Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. J Clin Oncol 2015;33:1078-85. [PMID: 25667275 DOI: 10.1200/JCO.2014.60.2557] [Cited by in Crossref: 74] [Cited by in F6Publishing: 24] [Article Influence: 10.6] [Reference Citation Analysis]
8 Zheng G, Sundquist K, Sundquist J, Försti A, Hemminki O, Hemminki K. Bladder and upper urinary tract cancers as first and second primary cancers. Cancer Rep (Hoboken) 2021;:e1406. [PMID: 34114732 DOI: 10.1002/cnr2.1406] [Reference Citation Analysis]
9 Bendle M, Pealing J, Papanastasopoulos P, Bower M. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS). Cancer Chemother Pharmacol 2014;74:611-5. [PMID: 25055936 DOI: 10.1007/s00280-014-2538-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
10 Teerlink CC, Albright FS, Lins L, Cannon-Albright LA. A comprehensive survey of cancer risks in extended families. Genet Med 2012;14:107-14. [PMID: 22237439 DOI: 10.1038/gim.2011.2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
11 Okajima K, Ishikawa K, Matsuura T, Tatebe H, Fujiwara K, Hiroi K, Hasegawa H, Nishimura Y. Multiple primary malignancies in patients with prostate cancer: increased risk of secondary malignancies after radiotherapy. Int J Clin Oncol 2013;18:1078-84. [PMID: 23179638 DOI: 10.1007/s10147-012-0496-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Soualhi A, Rammant E, George G, Russell B, Enting D, Nair R, Van Hemelrijck M, Bosco C. The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urol 2021;21:110. [PMID: 34404373 DOI: 10.1186/s12894-021-00876-7] [Reference Citation Analysis]
13 Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol 2011;27:208-14. [PMID: 21814311 DOI: 10.4103/0970-1591.82839] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
14 Van Hemelrijck M, Drevin L, Holmberg L, Garmo H, Adolfsson J, Stattin P. Primary cancers before and after prostate cancer diagnosis: Other Primary Cancers & Prostate Cancer. Cancer 2012;118:6207-16. [DOI: 10.1002/cncr.27672] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
15 Hodgson DC, van Leeuwen FE. Second Malignancy Risk After Treatment of Hodgkin Lymphoma. In: Engert A, Younes A, editors. Hodgkin Lymphoma. Cham: Springer International Publishing; 2015. pp. 375-409. [DOI: 10.1007/978-3-319-12505-3_24] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Hemminki K, Yu H, Hemminki O, Sundquist J. RE: Familial Cancer Clustering of Urothelial Cancer: A Population-Based Case–Control Study. JNCI: Journal of the National Cancer Institute 2018;110:1277-8. [DOI: 10.1093/jnci/djy053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Gangopadhyay A, Nath P, Khan MR, Biswas J. Bladder Carcinoma after ABVD Chemotherapy for Hodgkin's Lymphoma: A Case Report. Case Rep Oncol 2012;5:148-53. [PMID: 22666204 DOI: 10.1159/000338040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289-301. [PMID: 23529000 DOI: 10.1038/nrclinonc.2013.41] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 15.1] [Reference Citation Analysis]
19 Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012;30:3734-3745. [PMID: 23008293 DOI: 10.1200/jco.2012.41.8681] [Cited by in Crossref: 152] [Cited by in F6Publishing: 93] [Article Influence: 15.2] [Reference Citation Analysis]
20 Yu H, Hemminki O, Försti A, Sundquist K, Hemminki K. Familial Urinary Bladder Cancer with Other Cancers. European Urology Oncology 2018;1:461-6. [DOI: 10.1016/j.euo.2018.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
21 Ide H, Inoue S, Miyamoto H. The Role of Glucocorticoid Receptor Signaling in Bladder Cancer Progression. Cancers (Basel) 2018;10:E484. [PMID: 30518063 DOI: 10.3390/cancers10120484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
22 Read J, Symmons J, Palmer JM, Montgomery GW, Martin NG, Hayward NK. Increased incidence of bladder cancer, lymphoid leukaemia, and myeloma in a cohort of Queensland melanoma families. Fam Cancer 2016;15:651-63. [PMID: 27108303 DOI: 10.1007/s10689-016-9907-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]